AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2249406
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets plus 1000 ppmF- rinsing
Trial: 2249406
Drug: Active tablet/active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tablet/active rinse group
Trial: 2249406
Drug: Active tablet/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tablet/placebo rinse group
Trial: 2249406
Drug: Tablet-only children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-only children
Trial: 30730346
Drug: Intradermal Botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Botulinum Toxin (BTX) injections
Trial: 23095307
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg/2 weeks
Trial: 21172842
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) 20 mg/kg/day
Trial: 17652181
Drug: Cinacalcet 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet 50 mg orally once daily for 8 days
Trial: 11896478
Drug: Doxazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (4 mg daily) and sildenafil (100 mg 1 h before sexual intercourse)
Trial: 10213258
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment (S)
Trial: 3042876
Drug: WC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WC vaccine
Trial: 19064822
Drug: Half-dose TIV
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose TIV
Trial: 19064822
Drug: Full-dose TIV
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose TIV
Trial: 16100237
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg kg(‐1) in isotonic saline 0.2 ml kg(‐1)
Trial: 16100237
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg kg(‐1) in isotonic saline 0.2 ml kg(‐1)
Trial: 9710008
Drug: Diuretic (trichlormethiazide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (trichlormethiazide, 2 mg daily)
Trial: 9710008
Drug: NSAID-slow release
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID-slow release (tenoxicam-SR, 20 mg daily)
Trial: 9710008
Drug: Steroid (prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (prednisolone, 20 mg daily for 2 weeks, then 10 mg daily for 2 weeks)
Trial: 2841905
Drug: Carboplatin 300
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 300 mg/m2
Trial: 2841905
Drug: Carboplatin 400
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 400 mg/m2
Trial: 2841905
Drug: Carboplatin 450
RxNorm normalized name: CARBOPLATIN 450MG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin 450 mg/m2
Trial: 1244812
Drug: Calcium heparinate
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparinate (low doses, administered subcutaneously)
Trial: 1244812
Drug: Sodium pentosan
RxNorm normalized name: Pentosan Polysulfate Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium pentosan polysulfate (administered intramuscularly)
Trial: 25146365
Drug: Amlodipine camsylate/losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine camsylate/losartan 5/100 mg/d (AML/LOS)
Trial: 25146365
Drug: Losartan/hydrochlorothiazide 100/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan/hydrochlorothiazide 100/12.5 mg/d (LOS/HCTZ)
Trial: 20664127
Drug: Humor group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humor group (self-selected humor for 30 minutes daily)
Trial: 20664127
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard cardiac therapy)
Trial: 15458908
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/d or 120 mg/d
Trial: 11167350
Drug: Cetirizine (C)
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine (C) 10 mg daily for 2 weeks
Trial: 24283773
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 7.5 mg per week for 12 weeks
Trial: 21348912
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with dutasteride (0.5 mg) and tamsulosin (0.4 mg)
Trial: 19056900
Drug: 20,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 IU cholecalciferol twice a week
Trial: 19056900
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a week
Trial: 1655299
Drug: edrophonium 1
RxNorm normalized name: edrophonium 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edrophonium 1 mg.kg‐1 (single-dose)
Trial: 1655299
Drug: edrophonium 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edrophonium 0.75 mg.kg‐1 (single-dose)
Trial: 1655299
Drug: edrophonium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edrophonium 0.25 mg.kg‐1 followed by 0.75 mg.kg‐1 (divided-dose)
Trial: 1655299
Drug: edrophonium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edrophonium 0.25 mg.kg‐1 followed by 0.50 mg.kg‐1 (divided-dose)
Trial: 1655299
Drug: edrophonium (divided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edrophonium (divided doses)
Trial: 6751003
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment (25 mg hydrochlorothiazide and 50 mg triamterene)
Trial: 30711665
Drug: Directed training
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directed training for Instrumental Activities of Daily Living (IADL) using web-based programs for driving and fraud avoidance
Trial: 27911341
Drug: MAO-B inhibitors
RxNorm normalized name: MAO B Inhibitors, dopaminergic anti-parkinson drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAO-B inhibitors
Trial: 21941012
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g of NaHCO3 per kilogram body mass)
Trial: 21941012
Drug: Placebo (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.15 g of corn flour per kilogram body mass)
Trial: 19685757
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection 0.6 mL x kg(‐1) added to physiological saline 250 mL after anaesthesia before CPB
Trial: 19685757
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline 250 mL
Trial: 8526620
Drug: Duraflo II
RxNorm normalized name: Duraflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duraflo II heparin coat
Trial: 8526620
Drug: Carmeda Biological
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carmeda Biological Active Surface
Trial: 20535962
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine with high-dose IL-2
Trial: 20535962
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell (DC) vaccine of prostate-acid protein plus GM-CSF
Trial: 20535962
Drug: MAGE-A3 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAGE-A3 vaccine for non-small cell lung cancer
Trial: 12669250
Drug: Biochemotherapy (cisplatinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biochemotherapy (cisplatinum 30 mg/m2 days 1-3, DTIC 250 mg/m2 days 1-3 i.v., Interferon-alpha2b 10 MIU s.c. 3 days a week, on a 28-day cycle)
Trial: 8979185
Drug: No umbilical
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No umbilical catheter; peripheral intravenous lines only (control group)
Trial: 6427714
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms mestranol plus 0.5 mg ethynodiol diacetate (100 M + 0.5 ED)
Trial: 6427714
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms mestranol plus 1.0 mg ethynodiol diacetate (100 M + 1.0 ED)
Trial: 6427714
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms ethinyl estradiol plus 1.0 mg ethynodiol diacetate (50 EE + 1.0 ED)
Trial: 6427714
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms ethinyl estradiol plus 2.0 mg ethynodiol diacetate (30 EE + 2.0 ED)
Trial: 6427714
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms ethinyl estradiol plus 0.15 mg levonorgestrel (30 EE + 0.15 NG)
Trial: 30998422
Drug: Erythromycin (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (2% w/v) with zinc acetate (1.2% w/v) topical gel
Trial: 30998422
Drug: Erythromycin (2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (2% w/v) gel alone
Trial: 24411797
Drug: Drug positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug positive (marijuana and other drugs) among sober drivers
Trial: 24411797
Drug: Drug positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug positive (marijuana and other drugs) among drinking drivers
Trial: 24411797
Drug: Other drugs
RxNorm normalized name: Other drugs for bile therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drugs (excluding marijuana)
Trial: 15869543
Drug: Myobloc (botulinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myobloc (botulinum toxin type B) 2500 U (0.5 ml) per axilla
Trial: 15869543
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml vehicle (placebo)
Trial: 12672711
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (150 micro g of selenium, 2000 IU of retinol, 120 mg of ascorbic acid, 30 IU of alpha‐tocopherol) with taper training (TT)
Trial: 12672711
Drug: Taper training
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper training (TT)
Trial: 8808777
Drug: Combined dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined dipyridamole (150 mg) and aspirin (100 mg) pellet formulation
Trial: 8808777
Drug: Conventional products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional products (dipyridamole and aspirin) given twice daily
Trial: 2413307
Drug: Clonidine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.15 mg i.v.) plus Naloxone (0.4 mg i.v.)
Trial: 2413307
Drug: Naloxone (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4, 2.0, and 8.0 mg i.v.)
Trial: 30452784
Drug: Fulacimstat 5
RxNorm normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulacimstat 5 mg twice daily (n=9)
Trial: 30452784
Drug: Fulacimstat 10
RxNorm normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulacimstat 10 mg twice daily (n=9)
Trial: 30452784
Drug: Fulacimstat 25
RxNorm normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulacimstat 25 mg twice daily (n=10)
Trial: 30452784
Drug: Fulacimstat 50
RxNorm normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fulacimstat 50 mg once daily (n=9)
Trial: 27717303
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg per day on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day)
Trial: 27717303
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus letrozole (2.5 mg per day)
Trial: 20559229
Drug: Local cycloferon
RxNorm normalized name: Cicloferon
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local cycloferon liniment in comprehensive treatment of parodontitis
Trial: 17589833
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER 225 mg
Trial: 8784893
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection with 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Trial: 8784893
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection
Trial: 1461544
Drug: Nicardipine retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine retard (40 mg twice a day)
Trial: 1461544
Drug: Nicardipine retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine retard + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Trial: 1461544
Drug: Captopril +
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril + Hydrochlorothiazide (12.5 mg/day after 2 months if needed)
Trial: 6597708
Drug: Lidocaine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (40 mg, 2 ml of 2% lidocaine mixed with 50 ml of contrast medium)
Trial: 31502003
Drug: Fibrinogen/Thrombin-Coated Collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen/Thrombin-Coated Collagen Patch (TachoSil®)
Trial: 31502003
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no fibrin sealant patch)
Trial: 29661389
Drug: Esketamine (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (cumulative dose 40 mg infused in 1 h)
Trial: 26704011
Drug: Oral 500
RxNorm normalized name: OsCal 500 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 500 ml of 10% glucose solution two hours before surgery
Trial: 26704011
Drug: Trial group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial group (Oral carbohydrate) vs Control group (Fasting)
Trial: 24088271
Drug: IgM-enriched intravenous
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched intravenous immunoglobulin (IVIG)
Trial: 18444869
Drug: Switch arm
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch arm (half dose of stavudine)
Trial: 18444869
Drug: Continuation arm
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation arm (standard dose of stavudine)
Trial: 12657345
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg calcium supplement for 10 days
Trial: 9052302
Drug: PCEA HM
RxNorm normalized name: DEXTRAN HM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA HM 3‐mL (0.15 mg) bolus doses + saline 1 mL IV q6h (Group 1)
Trial: 9052302
Drug: PCEA HM
RxNorm normalized name: DEXTRAN HM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA HM (0.15 mg) in 0.125% bupivacaine 3‐mL bolus doses + saline 1 mL IV q6h (Group 2)
Trial: 9052302
Drug: PCEA HM
RxNorm normalized name: DEXTRAN HM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA HM 3‐mL (0.15 mg) bolus doses + ketorolac 1 mL (30 mg) IV q6h (Group 3)
Trial: 27455158
Drug: Preoperative chemical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Trial: 27455158
Drug: Postoperative chemical
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative chemical thromboprophylaxis (CTP) with 5000 units of subcutaneous heparin
Trial: 25415813
Drug: PTNS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTNS plus tolterodine (4 mg daily for three months)
Trial: 25415813
Drug: Tolterodine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine alone (4 mg daily for three months)
Trial: 16622748
Drug: JTE‐522 (tiracoxib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTE‐522 (tiracoxib) 150 mg once daily for 26 weeks
Trial: 16622748
Drug: JTE‐522 (tiracoxib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTE‐522 (tiracoxib) 200 mg once daily for 26 weeks
Trial: 16622748
Drug: JTE‐522 (tiracoxib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JTE‐522 (tiracoxib) 150 mg and 200 mg
Trial: 8810935
Drug: Regular human
RxNorm normalized name: insulin regular human recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular human insulin 100 U mL‐1 (Actrapid) at a dose of 160 U
Trial: 7917439
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about symptoms of nicotine withdrawal, means of abstaining during hospitalization, means of permanently quitting, or medications for nicotine withdrawal symptoms.
Trial: 2969315
Drug: cilazapril (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril (mean dose 3.6 +/- 0.9 mg/day)
Trial: 31185955
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control A)
Trial: 28320793
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg berryfruit polyphenolic extract (BFPE)
Trial: 19583714
Drug: Vaginal repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal repair with mesh augmentation (mesh group, n = 69)
Trial: 19583714
Drug: Vaginal repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal repair with mesh augmentation (mesh group)
Trial: 9516068
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of systolic hypertension with calcium antagonists
Trial: 1707109
Drug: Diltiazem (DZ)
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem (DZ) pretreatment and infusion (0.12 mg/kg/h for 74 hours starting 2 hours prior to surgery, continued with 90 mg b.i.d. p.o. until day 30)
Trial: 290726
Drug: Propoxyphene napsylate
RxNorm normalized name: Propoxyphene Napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene napsylate (50, 100, and 150 mg)
Trial: 290726
Drug: Fenoprofen calcium
RxNorm normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenoprofen calcium (200, 400, and 600 mg)
Trial: 290726
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propoxyphene (50/200, 100/400, and 150/600 mg)
Trial: 31310960
Drug: Simulated amniotic
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated amniotic fluid-like solution (SAFE)
Trial: 26306733
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy protocol (180 min of treatment/day for 10 days)
Trial: 26306733
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy protocol
Trial: 22899425
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for managing dysfunctional thoughts about caregiving and training in self-help techniques
Trial: 12678210
Drug: Isoflavone supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplements
Trial: 31183382
Drug: Traditional Karate
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Karate (60 minutes twice a week for at least one year)
Trial: 21684022
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy intervention (PTI)
Trial: 20801187
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment in orchiectomised rats
Trial: 16110692
Drug: Desmopressin 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.05 mg
Trial: 16110692
Drug: Desmopressin 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.10 mg
Trial: 16110692
Drug: Desmopressin 0.15
RxNorm normalized name: desmopressin 0.15 mg/inh nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.15 mg
Trial: 16110692
Drug: Desmopressin 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.20 mg